Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

  • Patel, Manish (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Tan, Pearlyn (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title17000139BLC2001
AcronymTAR-200
StatusActive
Effective start/end date13/08/21 → 15/04/26
View all
View less